Comparative Pharmacology
Head-to-head clinical analysis: EMRELIS versus PROMETHAZINE VC PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMRELIS versus PROMETHAZINE VC PLAIN.
EMRELIS vs PROMETHAZINE VC PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Emrelis is a monoclonal antibody that inhibits the interaction between programmed cell death protein 1 (PD-1) and its ligands PD-L1 and PD-L2, thereby activating T-cell-mediated antitumor immune response.
Promethazine is a phenothiazine derivative with antihistaminic (H1 receptor antagonist), sedative, antiemetic, and anticholinergic effects. Phenylephrine is a sympathomimetic amine acting primarily on alpha-1 adrenergic receptors, causing vasoconstriction.
100 mg subcutaneously once weekly.
Adults: 1 tablet (promethazine 6.25 mg, phenylephrine 10 mg) orally every 4-6 hours as needed, not to exceed 4 tablets in 24 hours.
None Documented
None Documented
12 hours (terminal); dosing interval adjusted in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is approximately 9–16 hours (mean ~12 hours) in adults; may be prolonged in hepatic impairment or elderly patients.
Renal: 70% unchanged; fecal: 15%; biliary: 10%
Primarily renal as inactive metabolites; approximately 70-80% excreted in urine, with about 20-30% in feces via biliary secretion. Less than 1% excreted unchanged.
Category C
Category A/B
Antiemetic
Antihistamine / Antiemetic